This bill requires insurers and health care plans to follow specific rules when using virtual credit cards or fee-based digital payment methods to reimburse healthcare providers. Insurers must first notify providers of any potential fees, offer a fee-free payment alternative, and get the provider's written consent within 30 days to use the fee-based method. If a provider doesn't respond in time, insurers must default to the fee-free option. The law applies directly to insurers and healthcare providers who contract with them, ensuring transparency and preventing unexpected charges for providers.
Expands health care services provided by telehealth to include services delivered through a facility licensed under article twenty-eight of the public health law that is eligible to be designated or has received a designation as a federally qualified health center, including those facilities that are also licensed under article thirty-one or article thirty-two of the mental hygiene law.
Establishes a three-year pilot hospital medical debt relief program to provide hospital medical debt relief to eligible residents of the state utilizing a not-for-profit organization to identify, acquire and cancel medical debt of such eligible residents directly from health care providers in the state.
Relates to requiring a medical facility or related service to obtain express prior written consent before filming and/or broadcasting of visual images of a patient's medical treatment.
This bill allows licensed pharmacists to order and administer specific medical tests, including COVID-19, flu, RSV, strep throat, HbA1c, hepatitis C, and HIV tests, all authorized by the FDA. It directly affects pharmacists (expanding their clinical role) and patients (increasing access to convenient testing). The law requires tests to meet FDA authorization and federal "waiver" requirements, aligning pharmacists with qualified health professionals under existing public health law. The bill modifies prior 2022 legislation but includes a sunset provision, with most provisions set to expire on July 1, 2028.
Relates to the provision of patient health information and medical records; expands the definition of medical records to include all health related records; prohibits fees for providing certain records.
Refers individuals to appropriate service providers that are able to provide services to such individual within seventy-two hours for substance use disorders.
S 3029 establishes a licensing system for genetic counselors in New York and creates a State Board for Genetic Counseling. To practice as a genetic counselor or use the title "genetic counselor," individuals must obtain a license by meeting requirements including a master's degree in genetic counseling, passing an exam, and demonstrating relevant experience. The bill prohibits unlicensed practice and restricts the title to licensed professionals, while defining genetic counseling as providing education about genetic risks and testing - without diagnosing or treating medical conditions. The State Board, composed of five licensed genetic counselors, one physician, and one public representative, will oversee licensing standards and professional conduct. This directly affects genetic counselors seeking to practice in New York and ensures consistent educational and professional standards for the public.
This bill sets minimum Medicaid reimbursement rates for private duty nursing services provided to eligible patients in New York. It requires payments to be at least 80% of the standard CHAMPUS/TRICARE rate for the New York area, effective July 1, 2026. The Department of Health must publish a detailed private duty nursing rate schedule at least 30 days before the effective date and annually thereafter. This directly affects Medicaid-enrolled patients receiving private duty nursing care and the home care providers who deliver these services.
Relates to program eligibility for plans comparable to Medicare part D; provides for analysis of health plans by the department of health to determine whether such health plans meet or exceed the Medicare part D standard; requires the department of health, in consultation with the department of financial services, to notify prescription drug insurers of the provisions of this act.
